News
Capen exhibit portrays military experiences of students, staff and faculty
An associate professor in the departments of Microbiology and Immunology, and Biochemistry in the School of Medicine and Biomedical Sciences, Melendy and his UB colleagues have been studying how the human papilloma virus (HPV) “hijacks” a cell’s DNA machinery in order to replicate its viral genome.
Currently, Melendy and his colleagues are working to develop an anti-viral drug against HPV infections, as well as strategies that would kill HPV cancer cells while leaving normal cells alone.
With parents questioning whether they should have their children vaccinated with Gardasil, the HPV vaccine, Melendy discusses his detailed knowledge of HPV and why children should be vaccinated.
HPV, or human papilloma viruses, have co-evolved with humans over millions of years. HPV infections are very common and almost everyone has one at some point in their lives. Most infections create a small benign wart, which is generally resolved by our immune systems. Some HPV strains only infect the outer skin, while others are sexually transmitted and only infect the genitalia or other mucosal surfaces.
HPV sexually transmitted infections are among the most common. Virtually one in nine people in the U.S. has an active HPV sexually transmitted infection at any time. Some require treatment; others may not even be apparent and resolve on their own. It is only the rare HPV infection, one in thousands of cases, that develops into cancer.
Cervical cancer is the third most common cancer in women in the U.S. It also causes almost all other anogenital cancers, and over half of oral cancers. This means that HPV causes more cancers than anything other than smoking. Unlike other cancers, such as breast cancer, the absence of a family history of cervical cancer provides little statistical protection. Genetic modifiers and environmental factors, such as smoking, play some role, but the overwhelming single predictor for HPV cancer is having a persistent HPV infection. While regular Pap smears help catch cervical cancer early, so it’s more treatable, nearly one in three cases still results in death in the U.S., and it’s one out of two cases worldwide. That’s approximately 5,000 deaths a year in the U.S. and 232,000 worldwide. Unlike most forms of cancer, cervical cancer often strikes early, killing women in the prime of their lives.
The HPV vaccine is clearly worthwhile. If given properly to all girls before they become sexually active, the HPV vaccine would prevent about two-thirds of cervical cancers; vaccinating boys, as well as girls, also will provide likely protection against other anogenital and oral cancers. Since HPV is such a common sexually transmitted infection, and since even condoms are only partially effective at preventing HPV transmission, the vaccine series needs to be given before people first become sexually active.
This is not a “risky” vaccine. It has no mercury-containing chemicals—for which no danger has been proven—but some people, nevertheless, remain concerned. There is no viral, genetic material so there is no danger of infecting anyone from the vaccination. While there are apocryphal reports of serious health consequences to a few young girls, there is absolutely no evidence at this point that the vaccine caused the negative health consequences attributed to it. To date, the number of cases that might have caused an unusual allergic response are so small—a handful—that the benefits of saving thousands of lives by the HPV vaccine far outweigh the risks for any individual.
Better vaccines, better treatments against HPV infection and better treatments for HPV-induced cancers are all necessary. This is a cancer that can, in many cases, be prevented through vaccination or, potentially, by early treatment of HPV infections—if new, anti-HPV drugs can be developed. HPV cancers are potentially far more amenable to cancer-specific treatments than are most cancers. Additional research funding in these areas could save thousands and thousands of lives every year.
Comments from current UB faculty, staff and students will be published directly on this page after a brief editorial review process. You will be asked to sign in with your UBITname and password after clicking “Post.” You may not be asked to sign in again if you have already signed in to other UB services (e.g. MyUB, webmail, etc.). The UB Reporter does not publish anonymous comments nor comments posted under a pseudonym. Comments are limited to 125 words; those needing more space to make their point should write a letter to the editor, rather than posting multiple comments. The UB Reporter editor reserves the right not to publish comments that, in the opinion of the editor, make substantially the same point the writer has made in a previous post and do not add anything new to the public discussion of the matter at hand. Please send letters and general comments to the editor using our feedback page.
Reader Comments